Concepts (143)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mitochondrial Diseases | 2 | 2024 | 20 | 1.590 |
Why?
|
| HIV Infections | 6 | 2024 | 2586 | 1.420 |
Why?
|
| Insulin Resistance | 2 | 2024 | 201 | 1.300 |
Why?
|
| DNA, Mitochondrial | 2 | 2024 | 191 | 0.920 |
Why?
|
| Diabetes Mellitus, Type 1 | 3 | 2015 | 92 | 0.800 |
Why?
|
| Growth Differentiation Factor 15 | 1 | 2021 | 2 | 0.730 |
Why?
|
| Fibroblast Growth Factors | 1 | 2021 | 36 | 0.720 |
Why?
|
| Histocompatibility Antigens Class I | 4 | 2013 | 32 | 0.650 |
Why?
|
| HIV-Associated Lipodystrophy Syndrome | 1 | 2019 | 31 | 0.610 |
Why?
|
| Adipocytes | 1 | 2019 | 60 | 0.590 |
Why?
|
| Adenosine Triphosphate | 1 | 2019 | 206 | 0.570 |
Why?
|
| T-Lymphocytes | 3 | 2021 | 386 | 0.530 |
Why?
|
| Major Histocompatibility Complex | 2 | 2012 | 29 | 0.460 |
Why?
|
| Infectious Disease Transmission, Vertical | 3 | 2024 | 74 | 0.460 |
Why?
|
| Mitochondria | 4 | 2024 | 523 | 0.460 |
Why?
|
| Child | 4 | 2024 | 3443 | 0.430 |
Why?
|
| Wolves | 1 | 2013 | 3 | 0.410 |
Why?
|
| Antigen Presentation | 1 | 2013 | 58 | 0.400 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2013 | 82 | 0.380 |
Why?
|
| Histocompatibility Antigens | 1 | 2012 | 12 | 0.370 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2012 | 31 | 0.370 |
Why?
|
| Adolescent | 5 | 2024 | 6081 | 0.370 |
Why?
|
| Anti-Retroviral Agents | 2 | 2024 | 160 | 0.370 |
Why?
|
| Peptides | 2 | 2012 | 372 | 0.360 |
Why?
|
| Autoimmunity | 1 | 2012 | 58 | 0.360 |
Why?
|
| Immunotherapy | 2 | 2015 | 144 | 0.360 |
Why?
|
| CD8-Positive T-Lymphocytes | 5 | 2016 | 184 | 0.330 |
Why?
|
| Cross-Sectional Studies | 4 | 2024 | 3156 | 0.330 |
Why?
|
| Infant | 2 | 2024 | 1175 | 0.310 |
Why?
|
| Child, Preschool | 2 | 2024 | 1546 | 0.290 |
Why?
|
| Dogs | 3 | 2013 | 204 | 0.280 |
Why?
|
| Humans | 13 | 2024 | 43102 | 0.240 |
Why?
|
| Cohort Studies | 2 | 2020 | 1759 | 0.230 |
Why?
|
| Pyruvic Acid | 1 | 2024 | 22 | 0.220 |
Why?
|
| Electron Transport Complex IV | 1 | 2024 | 41 | 0.210 |
Why?
|
| Electron Transport Complex I | 1 | 2024 | 29 | 0.210 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2016 | 279 | 0.210 |
Why?
|
| Oxidative Phosphorylation | 1 | 2024 | 60 | 0.210 |
Why?
|
| Male | 7 | 2024 | 23409 | 0.210 |
Why?
|
| Female | 6 | 2024 | 24698 | 0.200 |
Why?
|
| Lactic Acid | 1 | 2024 | 112 | 0.200 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2022 | 21 | 0.190 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2021 | 247 | 0.180 |
Why?
|
| Young Adult | 2 | 2024 | 5080 | 0.180 |
Why?
|
| Pregnancy | 2 | 2024 | 1772 | 0.170 |
Why?
|
| Protein Multimerization | 2 | 2012 | 115 | 0.170 |
Why?
|
| Risk | 1 | 2021 | 287 | 0.170 |
Why?
|
| Ethanolamine | 1 | 2021 | 6 | 0.170 |
Why?
|
| Case-Control Studies | 1 | 2024 | 1285 | 0.170 |
Why?
|
| Longitudinal Studies | 1 | 2024 | 1063 | 0.170 |
Why?
|
| Regression Analysis | 1 | 2021 | 490 | 0.160 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2021 | 458 | 0.160 |
Why?
|
| Phospholipids | 1 | 2021 | 70 | 0.160 |
Why?
|
| Myocardial Infarction | 1 | 2022 | 247 | 0.150 |
Why?
|
| Subcutaneous Fat | 1 | 2019 | 19 | 0.150 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2019 | 57 | 0.150 |
Why?
|
| Mutation | 1 | 2024 | 1177 | 0.150 |
Why?
|
| Selenoproteins | 1 | 2021 | 155 | 0.150 |
Why?
|
| Follow-Up Studies | 1 | 2021 | 1067 | 0.150 |
Why?
|
| Animals | 9 | 2022 | 16992 | 0.140 |
Why?
|
| Cytokines | 1 | 2021 | 678 | 0.140 |
Why?
|
| Chemotaxis | 1 | 2016 | 68 | 0.120 |
Why?
|
| Mice | 6 | 2022 | 6644 | 0.120 |
Why?
|
| Antibodies | 1 | 2016 | 144 | 0.120 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2016 | 69 | 0.120 |
Why?
|
| Alleles | 2 | 2013 | 352 | 0.110 |
Why?
|
| Immune Tolerance | 1 | 2015 | 68 | 0.110 |
Why?
|
| Anti-HIV Agents | 1 | 2019 | 486 | 0.110 |
Why?
|
| Amino Acid Sequence | 2 | 2013 | 1180 | 0.100 |
Why?
|
| Molecular Sequence Data | 2 | 2013 | 1542 | 0.100 |
Why?
|
| United States | 1 | 2024 | 5205 | 0.100 |
Why?
|
| Protein Isoforms | 1 | 2013 | 139 | 0.100 |
Why?
|
| Biological Assay | 1 | 2012 | 63 | 0.090 |
Why?
|
| Phylogeny | 2 | 2013 | 769 | 0.090 |
Why?
|
| Molecular Imaging | 1 | 2012 | 30 | 0.090 |
Why?
|
| Polymorphism, Genetic | 1 | 2012 | 201 | 0.090 |
Why?
|
| Promoter Regions, Genetic | 1 | 2013 | 526 | 0.080 |
Why?
|
| Genetic Variation | 1 | 2013 | 430 | 0.080 |
Why?
|
| Dietary Carbohydrates | 2 | 2006 | 34 | 0.080 |
Why?
|
| Bicycling | 2 | 2006 | 18 | 0.080 |
Why?
|
| Cell Line | 1 | 2013 | 1410 | 0.080 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2006 | 15 | 0.060 |
Why?
|
| Aged | 1 | 2019 | 8214 | 0.060 |
Why?
|
| Interleukin-8 | 1 | 2006 | 74 | 0.060 |
Why?
|
| Leukocytes | 1 | 2006 | 80 | 0.060 |
Why?
|
| Interleukin-10 | 1 | 2006 | 87 | 0.060 |
Why?
|
| Interleukin-6 | 1 | 2006 | 165 | 0.060 |
Why?
|
| Adult | 3 | 2019 | 13872 | 0.060 |
Why?
|
| Middle Aged | 1 | 2019 | 12222 | 0.050 |
Why?
|
| Signal Transduction | 1 | 2012 | 2157 | 0.050 |
Why?
|
| Phenylephrine | 1 | 2022 | 34 | 0.050 |
Why?
|
| Angiotensin II | 1 | 2022 | 102 | 0.050 |
Why?
|
| Fibrosis | 1 | 2022 | 169 | 0.040 |
Why?
|
| RNA, Messenger | 1 | 2006 | 1271 | 0.040 |
Why?
|
| Collagen | 1 | 2022 | 181 | 0.040 |
Why?
|
| Proteome | 1 | 2022 | 152 | 0.040 |
Why?
|
| Ethanolamines | 1 | 2021 | 9 | 0.040 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2021 | 51 | 0.040 |
Why?
|
| Phosphatidylethanolamines | 1 | 2021 | 17 | 0.040 |
Why?
|
| Glycosylphosphatidylinositols | 1 | 2021 | 19 | 0.040 |
Why?
|
| Lipogenesis | 1 | 2021 | 19 | 0.040 |
Why?
|
| Fibroblasts | 1 | 2022 | 281 | 0.040 |
Why?
|
| Glycolysis | 1 | 2021 | 71 | 0.040 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2021 | 74 | 0.040 |
Why?
|
| Exercise | 1 | 2006 | 692 | 0.040 |
Why?
|
| Metabolomics | 1 | 2021 | 95 | 0.040 |
Why?
|
| Myocardium | 1 | 2022 | 263 | 0.040 |
Why?
|
| Calcium | 1 | 2022 | 491 | 0.040 |
Why?
|
| Mice, Knockout | 1 | 2021 | 1035 | 0.030 |
Why?
|
| Islets of Langerhans | 1 | 2016 | 16 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2016 | 51 | 0.030 |
Why?
|
| Epinephrine | 2 | 2006 | 36 | 0.030 |
Why?
|
| Hydrocortisone | 2 | 2006 | 93 | 0.030 |
Why?
|
| Insulin-Secreting Cells | 1 | 2015 | 28 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2021 | 1455 | 0.030 |
Why?
|
| Lymphocytes | 1 | 2015 | 124 | 0.030 |
Why?
|
| B-Lymphocytes | 1 | 2015 | 189 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 2015 | 306 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2015 | 259 | 0.020 |
Why?
|
| Breeding | 1 | 2012 | 28 | 0.020 |
Why?
|
| Protein Subunits | 1 | 2012 | 93 | 0.020 |
Why?
|
| Homozygote | 1 | 2012 | 77 | 0.020 |
Why?
|
| Epitopes | 1 | 2012 | 157 | 0.020 |
Why?
|
| Genetic Loci | 1 | 2012 | 104 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2012 | 206 | 0.020 |
Why?
|
| Haplotypes | 1 | 2012 | 197 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2012 | 272 | 0.020 |
Why?
|
| Inflammation | 1 | 2016 | 758 | 0.020 |
Why?
|
| Cell Membrane | 1 | 2012 | 403 | 0.020 |
Why?
|
| Protein Binding | 1 | 2012 | 1082 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2012 | 876 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2012 | 1070 | 0.020 |
Why?
|
| Placebos | 1 | 2006 | 41 | 0.020 |
Why?
|
| Phytohemagglutinins | 1 | 2006 | 13 | 0.020 |
Why?
|
| Vasoconstrictor Agents | 1 | 2006 | 39 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 2006 | 69 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2006 | 249 | 0.010 |
Why?
|
| Killer Cells, Natural | 1 | 2006 | 104 | 0.010 |
Why?
|
| Neutrophils | 1 | 2006 | 145 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2012 | 2676 | 0.010 |
Why?
|
| Insulin | 1 | 2006 | 258 | 0.010 |
Why?
|
| Blood Glucose | 1 | 2006 | 389 | 0.010 |
Why?
|
| Monocytes | 1 | 2006 | 277 | 0.010 |
Why?
|